2 results
Approved WMOWill not start
To gather data to support global submissions/approvals for some models of the Ingenio device family.
Approved WMOPending
Main Objective:To demonstrate the superiority of galcanezumab versus placebo in the prevention of migraine in (at least) 1 of the following populations with migraine: the overall pediatric population (6 to 17 year-olds) or the adolescent population…